You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 252 No. 9, September 7, 1984 TABLE OF CONTENTS
  JAMA
  •  Online Features
  ARTICLES
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Opiate Antagonists and Thyrotropin-Releasing Hormone

I. Potential Role in the Treatment of Shock

Alan I. Faden, MD

JAMA. 1984;252(9):1177-1180.

Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

DURING the past decade, a large number of peptides have been found in the brain and spinal cord. These neuropeptides appear to act as transmitters or modulators and, in many cases, have been found to be colocalized in synaptic terminals with "classic" neurotransmitters. More specific physiological and pathophysiological roles for these substances have been suggested, ie, endogenous opioids (endorphins) in pain transmission and autonomic regulation. In 1978, J. W. Holaday and I proposed that endorphins were major factors contributing to the pathophysiology of shock and subsequently demonstrated that administration of opiate receptor antagonists, like naloxone hydrochloride, significantly improved physiological variables and survival in a variety of experimental shock models.1-3 In 1981, we showed that large pharmacologic doses of thyrotropin-releasing hormone (TRH), possibly by acting as a "physiological" antagonist of endorphin systems, also significantly improved cardiovascular function and survival in experimental shock.4 Since these initial reports, a large body of . . . [Full Text PDF of this Article]


Author Affiliations

From the Neurobiology Research Unit, Uniformed Services University of the Health Sciences, Bethesda, Md. Dr Faden is now with the Department of Neurology, Veterans Administration Medical Center, San Francisco.


Footnotes

Reprint requests to Department of Neurology, Veterans Administration Medical Center, 4150 Clement St, San Francisco, CA 94121.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1984 American Medical Association. All Rights Reserved.